TIGIT and hepatocellular carcinoma: • HBx silencing with siRNA enhances activity of CD8 T   cells and NK cells (98)• Anti-TREM2 mAb targets macrophages and improves   responsiveness to anti-PD-1 in mice (120, 121)• GPC3-targeting CAR T cell therapies in HCC   (101–103)• GPC3-targeted CAR NK therapy (104, 105)• Co-blockade of TIGIT/PD-1 restores ex-vivo functions   of CD8 TILs in HCC (68)